Navigation Links
Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
Date:3/20/2008

our clinical program for NPI-2358 and involve first-rate cancer research centers with unique expertise with this class of vascular disrupting agents," said Kobi M. Sethna, President and CEO, Nereus Pharmaceuticals, Inc.

Upon successful completion of the Phase 1b trial and determination of the recommended doses for the combined agents, Nereus expects to advance NPI-2358 into an international randomized Phase 2 study of approximately 150 patients at 30 centers late in 2008. Nereus is also evaluating NPI-2358 in other solid tumor indications.

About NPI-2358 -- A Novel Vascular Disrupting Agent

NPI-2358 is a vascular disrupting agent currently in clinical development for the treatment of cancer by Nereus. Initial results from a single-agent Phase 1 trial in various tumor types indicate NPI-2358 has a favorable safety profile, including cardiac safety. It is also being evaluated in a Phase 1b study in combination with docetaxel for the treatment of non-small cell lung cancer. NPI-2358 is one of over 200 synthetic analogues that were prepared following the discovery of the compound Halimide isolated from a marine fungus. In preclinical models of cancer, including lung, breast, sarcoma, colon and prostate, NPI-2358 demonstrated potent and selective anti-tumor effects in combination with docetaxel and other oncology therapies, as well as single-agent efficacy in a number of orthotopic models. NPI-2358 interacts with soluble beta-tubulin and prevents the polymerization of tubulin without altering dynamic microtubule function of formed microtubules. As demonstrated in preclinical testing, this target profile results in a highly specific nanomolar cytotoxicity while reducing the side effects seen in first-generation VDAs due to cardiotoxicity, hemodynamic changes and neuropathies.

About Nereus Pharmaceuticals, Inc.

Nereus Pharmaceuticals pursues novel sources of chemical diversity to discover and develop new therapeutics. Using its unmatched
'/>"/>

SOURCE Nereus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... - DAPTACEL vaccine is licensed for the entire immunization ... protect against diphtheria, tetanus, and pertussis -, ... Pasteur, the vaccines division of the sanofi-aventis Group,announced today ... DAPTACEL(R) (Diphtheria and Tetanus Toxoids and Acellular,Pertussis Vaccine Adsorbed) ...
... Silence Therapeutics plc,(AIM: SLN) today announces a collaboration ... a range of novel approaches for the delivery,of ... leading,expertise in the delivery of siRNA molecules, in ... siRNA in vivo using its,proprietary AtuPLEX technology. The ...
... March 13 Proteon Therapeutics, Inc.,( http://www.proteontherapeutics.com ... first-in-class pharmaceuticals to address the,medical needs of ... appointed,Gregory D. Phelps, a seasoned biopharmaceutical executive, ... brings more than 30 years of executive,leadership ...
Cached Biology Technology:U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 2U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 3U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series 4Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 2Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 3Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors 2
(Date:4/20/2014)... lung, breast and pancreatic cancers also promote drug-resistance and ... California, San Diego School of Medicine have discovered a ... drug-resistant tumors that appears responsible for inducing tumor metastasis ... , The findings, published in the April 20, ... may point to new therapeutic opportunities for reversing drug ...
(Date:4/18/2014)... contraceptive pills in Peru found that 28 percent ... quality or falsified. Many pills released the active ... ingredient. One batch had no active ingredient at ... researchers at the Georgia Institute of Technology developed ... assess suspected counterfeit drugs and then characterize their ...
(Date:4/18/2014)... NC Ancient DNA adds a twist to the story ... to be published April 21 in the journal Proceedings ... from the bones of chickens that lived 200-2300 years ago ... ago domestic chickens may have looked far different from the ... of the traits we associate with modern domestic chickens -- ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2
... that bacteria that cause diseases like bubonic plague and ... them infectious on or off. , Knowing how disease-causing ... may one day help scientists create drugs that control ... harmless, said Vladimir Svetlov, a study co-author and a ...
... how a protein from a bacterium acts like a cunningly ... of a new range of natural insecticides. It had been known that ... of a bacterium which they harbour inside their intestine. , The ... the nematode to kill and feed on the dead body of the ...
... reveal how illusions are produced in the brain's visual cortex, ... evidence of rapid integration of auditory and visual sensations in ... neural mechanisms by which visual perception can be altered by ... 12 edition of the Journal of Neuroscience. , When ...
Cached Biology News:Bacteria control how infectious they become, study finds 2Bacteria control how infectious they become, study finds 3Secret of worm's poison pill box protein could produce new natural insecticide 2Wired for sound: How the brain senses visual illusions 2
Artisan™ Wash Solution (x 50) Additional Information: EU regulatory status: CE US regulatory status: IVD ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
... stain is used to stain and visualize ... gels and does not interfere with northern ... transilluminator, the stain emits a red-orange signal ... or with a CCD camera-based gel documentation ...
... mitochondrial transmembrane potential is one ... that occur following induction of ... Kit utilizes a lipophilic cation, ... mitochondrial activity marker. MitoLight partitions ...
Biology Products: